BGA006

About Biogenera

Biogenera is a private, pre-revenue biotech firm pioneering a novel class of DNA-based therapeutics using its proprietary Peptide Nucleic Acid (PNA) platform, MyGenera™. Its lead candidate, BGA002, targets the MYCN oncogene for pediatric cancers and has received Orphan Drug Designations, positioning it for clinical development. The company maintains a diversified preclinical pipeline targeting key oncology drivers like MYC and BCL2, as well as undisclosed metabolic and dermatological diseases, leveraging academic and industry partnerships to advance its programs.

Therapeutic Areas